We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Horizon Discovery and Diatech Pharmacogenetics Sign Distribution Agreement

News   Apr 15, 2013

 
Horizon Discovery and Diatech Pharmacogenetics Sign Distribution Agreement
 
 
 

RELATED ARTICLES

One Year Later: CRISPR Success in Duchenne Muscular Dystrophy Model

News

Researchers have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease -- Duchenne muscular dystrophy (DMD) -- for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.

READ MORE

Can Fear Memories Be Extinguished?

News

Researchers have discovered a DNA modification that enhances our ability to extinguish fear. The findings could help guide the development of new treatments for fear-related anxiety disorders.

READ MORE

CRISPR Engineered “Invisible” Immune Cells

News

scientists have used the CRISPR-Cas9 gene-editing system to create the first pluripotent stem cells that are functionally "invisible" to the immune system, a feat of biological engineering that, in laboratory studies, prevented rejection of stem cell transplants.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Diagnostics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE